52 related articles for article (PubMed ID: 36043545)
1. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?
Romero A; Laurent C; Lebourg L; Lemée V; Hanoy M; Le Roy F; Grange S; Lemoine M; Guerrot D; Bertrand D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543747
[No Abstract] [Full Text] [Related]
2. The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.
Glhoom S; Fergany A; El-Araby D; Abdelkhalek AA; Gomaa A; Zayed EO; Abd-ElGwad M
Eur J Med Res; 2024 Jan; 29(1):27. PubMed ID: 38183123
[TBL] [Abstract][Full Text] [Related]
3. Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants?
Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Svizzeretto E; Tommasi A; Pallotto C; Schiaroli E; Francisci D
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543720
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.
Ordaya EE; Higgins EM; Vergidis P; Razonable RR; Beam E
Transpl Infect Dis; 2023 Jun; 25(3):e14040. PubMed ID: 36847413
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.
Simone S; Pronzo V; Pesce F; Bavaro DF; Infante B; Mercuri S; Schirinzi A; Panaro A; Conte E; Belati A; Troise D; Pontrelli P; Conserva F; Gallo P; Panico M; Spilotros M; Lucarelli G; Saracino A; Stallone G; Di Serio F; Ditonno P; Gesualdo L
J Nephrol; 2024 May; ():. PubMed ID: 38780697
[TBL] [Abstract][Full Text] [Related]
6. Tixagevimab/cilgavimab for the prevention of COVID-19 in solid organ transplant recipients.
Eribes E; Votruba C; Tinkham T; Huang A; Ilges D; Kunze K; Hudson M
Clin Transplant; 2024 Feb; 38(2):e15261. PubMed ID: 38375915
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023.
Solera JT; Árbol BG; Mittal A; Hall V; Marinelli T; Bahinskaya I; Selzner N; McDonald M; Schiff J; Sidhu A; Humar A; Kumar D
Am J Transplant; 2024 Mar; ():. PubMed ID: 38499087
[TBL] [Abstract][Full Text] [Related]
8. Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention.
Trepl J; Pasin C; Schneidawind D; Mueller NJ; Manz MG; Bankova AK; Abela IA
Br J Haematol; 2024 May; 204(5):1908-1912. PubMed ID: 38327109
[TBL] [Abstract][Full Text] [Related]
9. Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients.
Frączkiewicz J; Pawińska-Wąsikowska K; Szymbor K; Balwierz W; Skoczeń S; Czyżewski K; Kołtan S; Styczyński J; Małecka A; Irga-Jaworska N; Trelińska J; Młynarski W; Zając-Spychała O; Sobkowiak-Sobierajska A; Derwich K; Bal W; Chaber R; Książek A; Szczepański T; Zawitkowska J; Drabko K; Chodała-Grzywacz A; Karolczyk G; Kobierzycki C; Kałwak K
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610794
[No Abstract] [Full Text] [Related]
10. Patient-reported outcomes after Tixagevimab and Cilgavimab pre-exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk.
Alejo JL; Kim JD; Chiang TPY; Avery RK; Karaba AH; Jefferis A; Warren DS; Massie AB; Tobian AAR; Segev DL; Werbel WA
Clin Transplant; 2023 Apr; 37(4):e14913. PubMed ID: 36651598
[TBL] [Abstract][Full Text] [Related]
11. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab.
Aihara R; Umemura K; Katada Y; Nakagawa S; Kobayashi T; Hatano E; Date H; Nagao M; Terada T
J Infect Chemother; 2024 May; ():. PubMed ID: 38777151
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-coronavirus disease policy in China: A prospective, observational study.
Zhang W; Wang R; Jin P; Yu X; Wang W; Zhang Y; Bai X; Liang T
Am J Transplant; 2024 Apr; 24(4):631-640. PubMed ID: 37863433
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Evusheld safety and efficacy in multiple sclerosis patients.
Liu EN; Real M; Yang JH; Fair A; Whitmire N; Perez A; Wilder C; Rosengren S; Kinkel RP; Graves JS
Mult Scler Relat Disord; 2024 Jun; 88():105733. PubMed ID: 38901372
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 update: An EUA for pemivibart (Pemgarda) for pre-exposure prophylaxis.
Med Lett Drugs Ther; 2024 May; 66(1702):79-80. PubMed ID: 38696314
[No Abstract] [Full Text] [Related]
15. Comprehensive procedure for injecting Evusheld® for hematological diseases in a single institute.
Imataki O; Yoshida S; Ishida T; Uemura M; Fujita H; Kadowaki N
Ann Hematol; 2024 May; ():. PubMed ID: 38734996
[TBL] [Abstract][Full Text] [Related]
16. Discursive trends in New York Times coverage of Evusheld access: A case study in the social production of ignorance.
Goggins S
Soc Sci Med; 2024 May; 349():116855. PubMed ID: 38642521
[TBL] [Abstract][Full Text] [Related]
17. Protective measures against Omicron could be more effective than Evusheld® in liver transplant recipients.
Odriozola Herrán A; Fortea Ormaechea JI; Cuadrado A; Puente Sánchez Á; Lazarus JV; Crespo J; Fábrega E
Rev Esp Enferm Dig; 2022 Dec; 114(12):769-770. PubMed ID: 36043545
[TBL] [Abstract][Full Text] [Related]
18. Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.
Angelico R; Romano F; Coppola L; Materazzo M; Pedini D; Santicchia MS; Cacciola R; Toti L; Sarmati L; Tisone G
Medicina (Kaunas); 2023 Nov; 59(12):. PubMed ID: 38138204
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
